Credit Suisse
NAUT icon

Credit Suisse’s Nautilus Biotechnolgy NAUT Stock Holding History

Credit Suisse’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$4 – 3562
2022
Q4 		$4 Sell
2
-264
-99% -$510 ﹤0.01% 3844
2022
Q3 		$1K Buy
266
+209
+367% +$526 ﹤0.01% 3880
2022
Q2 		$0 Buy
+57
New +$212 ﹤0.01% 4169

Other funds holding NAUT

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Credit Suisse's NAUT Position: Q1 2023 in Review

Credit Suisse sold out of Nautilus Biotechnolgy (NAUT) in Q1 2023, closing a stake of 2 shares — an estimated $4 sold.

Credit Suisse first reported a position in NAUT in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 73 funds tracked by Wall St. Rank hold NAUT as of Q1 2023.

  • Credit Suisse reported no remaining Nautilus Biotechnolgy position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 2 Nautilus Biotechnolgy shares in Q1 2023, an estimated $4.
  • Credit Suisse first reported a position in Nautilus Biotechnolgy in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Nautilus Biotechnolgy position peaked at $1K in Q3 2022.
  • 73 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.